Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intraperitoneal administration of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor in patients undergoing appendectomy is safe: a phase II clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Simvastatin improves mitochondrial respiration in peripheral blood cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-term mortality in the Intermediate care after emergency abdominal surgery (InCare) trial - a post-hoc follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence of Infective Endocarditis in Streptococcal Bloodstream Infections is Dependent on Streptococcal Species

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. More than one-third of Cochrane reviews had gift authors, whereas ghost authorship was rare

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Group authorships in Cochrane had low compliance with Cochrane recommendations

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

We aimed to investigate the safety of intraperitoneal administration of the combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing appendectomy. We conducted a prospective phase II clinical trial in 14 otherwise healthy men suffering from uncomplicated appendicitis. After appendectomy, the trial treatment was administered intraperitoneally and left in the abdominal cavity. Trial treatment consisted of 4 g fosfomycin, 1 g metronidazole, and 50 µg rhGM-CSF in a total volume of 500 ml. Safety was evaluated through white blood cell count where a toxic effect was predefined. We evaluated harms and adverse events, repeated biochemical markers, vital signs, and length of stay. White blood cell count did not drop below the toxic range. The recorded harms were dizziness, discomfort when breathing deeply, no flatus, and bloating. Adverse events included three patients with diarrhoea after discharge and one patient with a hypotensive episode. No serious adverse events or infectious complications occurred. Intraperitoneal administration of fosfomycin, metronidazole, and rhGM-CSF was safe in otherwise healthy men undergoing laparoscopic appendectomy. There were some possible harms and adverse events but we were unable to assess if they were related to anaesthesia, surgery, or the trial treatment.

Original languageEnglish
Article number6727
JournalScientific Reports
Volume9
Issue number1
Pages (from-to)1-8
Number of pages8
ISSN2045-2322
DOIs
Publication statusPublished - 30 Apr 2019

ID: 57442744